We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.46 | -0.93% | 49.00 | 49.00 | 49.95 | 49.595 | 48.97 | 49.48 | 1,113,911 | 01:00:00 |
From May 2019 to May 2024
By Bowdeya Tweh
Sanofi SA (SAN.FR, SNY) and Merck & Co. (MRK) have received approval from U.S. health regulators for their drug designed to vaccinate children against diseases including tetanus, whooping cough and polio, the drugmakers said Wednesday.
The Food and Drug Administration has approved Vaxelis for use in a three-dose series of injections in children from 6 weeks old through age 4. Vaxelis was developed to vaccinate children against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and disease due to Haemophilus influenzae type B.
The companies said a commercial supply of Vaxelis won't be available in the U.S. until 2020, but added they would work to maximize production to ensure a sustainable supply of the drug.
Health regulators in Europe cleared Vaxelis to be sold in certain European countries in 2016.
Write to Bowdeya Tweh at bowdeya.tweh@wsj.com
(END) Dow Jones Newswires
December 26, 2018 15:52 ET (20:52 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
